Pulrodemstat Methylbenzenesulfonate(Synonyms: CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Pulrodemstat Methylbenzenesulfonate (Synonyms: CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate)

CC-90011 Methylbenzenesulfonate 是一种有效的，选择性的，可逆的和具有口服活性的赖氨酸特异性脱甲基酶-1 (LSD1) 抑制剂，IC50 为 0.25 nM。CC-90011 Methylbenzenesulfonate 对 LSD2，MOA-A 和 MAO-B 的酶抑制作用较小。CC-90011 Methylbenzenesulfonate 诱导急性髓细胞性白血病 (AML)和小细胞肺癌 (SCLC) 细胞分化，并具有有效的抗癌活性。

Pulrodemstat Methylbenzenesulfonate(Synonyms: CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate)

Pulrodemstat Methylbenzenesulfonate Chemical Structure

CAS No. : 2097523-57-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Pulrodemstat Methylbenzenesulfonate 的其他形式现货产品:

Pulrodemstat benzenesulfonate

生物活性

CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity[1].

IC50 & Target

IC50: 0.25 nM (LSD1)[1]
体外研究
(In Vitro)

CC-90011 (Compound 11) shows potent induction of on-target cellular differentiation marker CD11b in THP-1 cell line with an EC50 of 7 nM, antiproliferative activity in AML kasumi-1 cells with an EC50 of 2 nM[1].
Suppression of GRP is observed with treatment of CC-90011 (4 days) in a dose-dependent manner and at pharmacologically useful concentrations (EC50=3 nM, H209 and 4 nM, H1417). CC-90011 (12 days) treatment of SCLC cells results in potent antiproliferative activity (EC50=6 nM, H1417) that correlated with GRP suppression[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

CC-90011 (5 mg/kg; oral administration; daily; for 30 days; for 30 days) treatment inhibits tumor growth in patient-derived xenograft SCLC models[1].
CC-90011 (once a day; for 4 days) treatment results in robust downregulation of GRP mRNA levels at 2.5 mg/kg and maximum suppression of GRP at 5 mg/kg in a SCLC human tumor xenograft (H1417) mice[1].
After i.v. administration, CC-90011 (Compound 11; 5 mg/kg) has systemic clearance of 32.4 mL/min/kg, elimination half-life of 2 h, and a high volume of distribution of 7.5 L/kg. CC-90011 (Compound 11; 5 mg/kg) is readily absorbed after oral administration with an AUC0-24h of 1.8 μM·h, C/sub>max of 0.36 μM, and oral bioavailability of 32%[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice bearing small cell lung carcinoma (SCLC)[1]
Dosage: 5 mg/kg
Administration: Oral administration; daily; for 30 days
Result: Showed a tumor growth inhibition (TGI) of 78% at 5 mg/kg with no body weight loss.

Clinical Trial

分子量

623.67

Formula

C31H31F2N5O5S
CAS 号

2097523-57-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Toufike Kanouni, et al. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务